Radiopharmaceuticals in Nuclear Medicine Market Size, Share, Growth, and Industry Analysis, By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Others), By Application (Hospitals, Specialty Clinics, Diagnostic Centers, Others), Regional Insights and Forecast to 2035

Table of Content

1 Market Overview
1.1 Product Definition and Market Characteristics
1.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size
1.3 Market Segmentation
1.4 Regulatory Environment

2 Industry Chain Analysis
2.1 Industry Chain Analysis
2.2 Radiopharmaceuticals in Nuclear Medicine Raw Materials Analysis
2.2.1 Key Raw Materials Introduction
2.2.2 Key Suppliers of Raw Materials
2.3 Radiopharmaceuticals in Nuclear Medicine Business Mode and Production Process
2.3.1 Radiopharmaceuticals in Nuclear Medicine Business Mode Analysis
2.3.2 Production Process Analysis
2.4 Radiopharmaceuticals in Nuclear Medicine Cost Structure Analysis
2.4.1 Manufacturing Cost Structure of Radiopharmaceuticals in Nuclear Medicine
2.4.2 Raw Material Cost of Radiopharmaceuticals in Nuclear Medicine
2.4.3 Labor Cost of Radiopharmaceuticals in Nuclear Medicine
2.5 Market Channel Analysis
2.6 Major Downstream Customers Analysis
2.7 Alternative Product Analysis

3 Market Dynamics
3.1 Market Drivers
3.2 Market Constraints and Challenges
3.3 Emerging Market Trends
3.4 PESTEL Analysis
3.5 Consumer Insights Analysis
3.6 Impact of Russia and Ukraine War

4 Market Competitive Landscape
4.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue and Market Share by Manufacturer (2021-2026)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume and Market Share by Manufacturer (2021-2026)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Manufacturer (2021-2026)
4.4 Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
4.5 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Manufacturing Base Distribution and Headquarters
4.6 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Product Offered and Application
4.7 Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation and Trends
4.7.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Rate
4.7.2 Global Top 3 and Top 6 Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue
4.8 Industry News
4.8.1 Key Product Launch News
4.8.2 Mergers & Acquisitions, Expansion Plans

5 Global Radiopharmaceuticals in Nuclear Medicine Market Historical Development by Geographic Region (2021-2026)
5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Historical Sales Volume by Geographic Region (2021-2026)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Market Historical Revenue by Geographic Region (2021-2026)
5.3 North America Radiopharmaceuticals in Nuclear Medicine Market Status by Country (2021-2026)
5.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Volume by Country (2021-2026)
5.3.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026)
5.3.3 United States Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.3.4 Canada Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.4 Europe Radiopharmaceuticals in Nuclear Medicine Market Status by Country (2021-2026)
5.4.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Volume by Country (2021-2026)
5.4.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026)
5.4.3 Germany Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.4.4 France Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.4.5 United Kingdom Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.4.6 Spain Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.4.7 Russia Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.4.8 Poland Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.5 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Status by Country (2021-2026)
5.5.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Volume by Country (2021-2026)
5.5.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026)
5.5.3 China Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.5.4 Japan Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.5.5 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.5.6 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.5.7 India Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.5.8 Australia Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.6 Latin America Radiopharmaceuticals in Nuclear Medicine Market Status by Country (2021-2026)
5.6.1 Latin America Radiopharmaceuticals in Nuclear Medicine Sales Volume by Country (2021-2026)
5.6.2 Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026)
5.6.3 Mexico Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.6.4 Brazil Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.7 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Status by Country (2021-2026)
5.7.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume by Country (2021-2026)
5.7.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026)
5.7.3 GCC Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)
5.7.4 South Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue and Growth (2021-2026)

6 Global Radiopharmaceuticals in Nuclear Medicine Market Historical Development by Product Type (2021-2026)
6.1 Radiopharmaceuticals in Nuclear Medicine Definition by Type
6.2 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume by Product Type (2021-2026)
6.3 Global Radiopharmaceuticals in Nuclear Medicine Historical Revenue by Product Type (2021-2026)
6.4 Global Radiopharmaceuticals in Nuclear Medicine Historical Price by Product Type (2021-2026)
6.5 Global Historical Sales Volume, Revenue and Growth Rate by Product Type (2021-2026)
6.5.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume, Revenue and Growth Rate of Diagnostic Nuclear Medicine (2021-2026)
6.5.2 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume, Revenue and Growth Rate of Therapeutic Nuclear Medicine (2021-2026)
6.5.3 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume, Revenue and Growth Rate of Others (2021-2026)

7 Global Radiopharmaceuticals in Nuclear Medicine Market Historical Development by End User (2021-2026)
7.1 Downstream Market Overview
7.2 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume by End User (2021-2026)
7.3 Global Radiopharmaceuticals in Nuclear Medicine Historical Revenue by End User (2021-2026)
7.4 Global Radiopharmaceuticals in Nuclear Medicine Historical Price by End User (2021-2026)
7.5 Global Historical Sales Volume, Revenue and Growth Rate by End User (2021-2026)
7.5.1 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume, Revenue and Growth Rate of Hospitals (2021-2026)
7.5.2 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume, Revenue and Growth Rate of Specialty Clinics (2021-2026)
7.5.3 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume, Revenue and Growth Rate of Diagnostic Centers (2021-2026)
7.5.4 Global Radiopharmaceuticals in Nuclear Medicine Historical Sales Volume, Revenue and Growth Rate of Others (2021-2026)

8 Leading Companies Profiles
8.1 Institute Of Radioelement (IRE)
8.1.1 Institute Of Radioelement (IRE) Corporation Information
8.1.2 Institute Of Radioelement (IRE) - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.1.3 Institute Of Radioelement (IRE) Performance Analysis (2021-2026)
8.1.4 Institute Of Radioelement (IRE) Business and Markets Served
8.1.5 Institute Of Radioelement (IRE) Recent Developments
8.2 GE Healthcare (Subsidiary Of General Electric Company)
8.2.1 GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
8.2.2 GE Healthcare (Subsidiary Of General Electric Company) - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.2.3 GE Healthcare (Subsidiary Of General Electric Company) Performance Analysis (2021-2026)
8.2.4 GE Healthcare (Subsidiary Of General Electric Company) Business and Markets Served
8.2.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments
8.3 Cardinal Health, Inc.
8.3.1 Cardinal Health, Inc. Corporation Information
8.3.2 Cardinal Health, Inc. - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.3.3 Cardinal Health, Inc. Performance Analysis (2021-2026)
8.3.4 Cardinal Health, Inc. Business and Markets Served
8.3.5 Cardinal Health, Inc. Recent Developments
8.4 Taiyo Nippon Sanso Corporation
8.4.1 Taiyo Nippon Sanso Corporation Corporation Information
8.4.2 Taiyo Nippon Sanso Corporation - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.4.3 Taiyo Nippon Sanso Corporation Performance Analysis (2021-2026)
8.4.4 Taiyo Nippon Sanso Corporation Business and Markets Served
8.4.5 Taiyo Nippon Sanso Corporation Recent Developments
8.5 Institute of Atomic Energy Polatom Radioisotope Centre
8.5.1 Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
8.5.2 Institute of Atomic Energy Polatom Radioisotope Centre - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.5.3 Institute of Atomic Energy Polatom Radioisotope Centre Performance Analysis (2021-2026)
8.5.4 Institute of Atomic Energy Polatom Radioisotope Centre Business and Markets Served
8.5.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments
8.6 Cambridge Isotope Laboratories, Inc.
8.6.1 Cambridge Isotope Laboratories, Inc. Corporation Information
8.6.2 Cambridge Isotope Laboratories, Inc. - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.6.3 Cambridge Isotope Laboratories, Inc. Performance Analysis (2021-2026)
8.6.4 Cambridge Isotope Laboratories, Inc. Business and Markets Served
8.6.5 Cambridge Isotope Laboratories, Inc. Recent Developments
8.7 IBA Group
8.7.1 IBA Group Corporation Information
8.7.2 IBA Group - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.7.3 IBA Group Performance Analysis (2021-2026)
8.7.4 IBA Group Business and Markets Served
8.7.5 IBA Group Recent Developments
8.8 Urenco Limited
8.8.1 Urenco Limited Corporation Information
8.8.2 Urenco Limited - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.8.3 Urenco Limited Performance Analysis (2021-2026)
8.8.4 Urenco Limited Business and Markets Served
8.8.5 Urenco Limited Recent Developments
8.9 Institute of Isotopes Co., Ltd.
8.9.1 Institute of Isotopes Co., Ltd. Corporation Information
8.9.2 Institute of Isotopes Co., Ltd. - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.9.3 Institute of Isotopes Co., Ltd. Performance Analysis (2021-2026)
8.9.4 Institute of Isotopes Co., Ltd. Business and Markets Served
8.9.5 Institute of Isotopes Co., Ltd. Recent Developments
8.10 Bracco Imaging S.P.A.
8.10.1 Bracco Imaging S.P.A. Corporation Information
8.10.2 Bracco Imaging S.P.A. - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.10.3 Bracco Imaging S.P.A. Performance Analysis (2021-2026)
8.10.4 Bracco Imaging S.P.A. Business and Markets Served
8.10.5 Bracco Imaging S.P.A. Recent Developments
8.11 Eczacibasi-Monrol
8.11.1 Eczacibasi-Monrol Corporation Information
8.11.2 Eczacibasi-Monrol - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.11.3 Eczacibasi-Monrol Performance Analysis (2021-2026)
8.11.4 Eczacibasi-Monrol Business and Markets Served
8.11.5 Eczacibasi-Monrol Recent Developments
8.12 Isotec, Inc. (Sigma-Aldrich)
8.12.1 Isotec, Inc. (Sigma-Aldrich) Corporation Information
8.12.2 Isotec, Inc. (Sigma-Aldrich) - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.12.3 Isotec, Inc. (Sigma-Aldrich) Performance Analysis (2021-2026)
8.12.4 Isotec, Inc. (Sigma-Aldrich) Business and Markets Served
8.12.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments
8.13 Nordion, Inc.
8.13.1 Nordion, Inc. Corporation Information
8.13.2 Nordion, Inc. - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.13.3 Nordion, Inc. Performance Analysis (2021-2026)
8.13.4 Nordion, Inc. Business and Markets Served
8.13.5 Nordion, Inc. Recent Developments
8.14 Ntp Radioisotopes (Pty), Ltd.
8.14.1 Ntp Radioisotopes (Pty), Ltd. Corporation Information
8.14.2 Ntp Radioisotopes (Pty), Ltd. - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.14.3 Ntp Radioisotopes (Pty), Ltd. Performance Analysis (2021-2026)
8.14.4 Ntp Radioisotopes (Pty), Ltd. Business and Markets Served
8.14.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments
8.15 Fujifilm Holdings Corporation
8.15.1 Fujifilm Holdings Corporation Corporation Information
8.15.2 Fujifilm Holdings Corporation - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.15.3 Fujifilm Holdings Corporation Performance Analysis (2021-2026)
8.15.4 Fujifilm Holdings Corporation Business and Markets Served
8.15.5 Fujifilm Holdings Corporation Recent Developments
8.16 Covidien, Plc
8.16.1 Covidien, Plc Corporation Information
8.16.2 Covidien, Plc - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.16.3 Covidien, Plc Performance Analysis (2021-2026)
8.16.4 Covidien, Plc Business and Markets Served
8.16.5 Covidien, Plc Recent Developments
8.17 Australian Nuclear Association And Technology Organization (ANSTO)
8.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
8.17.2 Australian Nuclear Association And Technology Organization (ANSTO) - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Performance Analysis (2021-2026)
8.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Business and Markets Served
8.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments
8.18 Siemens Healthcare (Subsidiary Of Siemens AG)
8.18.1 Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
8.18.2 Siemens Healthcare (Subsidiary Of Siemens AG) - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.18.3 Siemens Healthcare (Subsidiary Of Siemens AG) Performance Analysis (2021-2026)
8.18.4 Siemens Healthcare (Subsidiary Of Siemens AG) Business and Markets Served
8.18.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments
8.19 Rotem Industries, Ltd., Inc.
8.19.1 Rotem Industries, Ltd., Inc. Corporation Information
8.19.2 Rotem Industries, Ltd., Inc. - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.19.3 Rotem Industries, Ltd., Inc. Performance Analysis (2021-2026)
8.19.4 Rotem Industries, Ltd., Inc. Business and Markets Served
8.19.5 Rotem Industries, Ltd., Inc. Recent Developments
8.20 Board of Radiation And Isotope Technology (BRIT)
8.20.1 Board of Radiation And Isotope Technology (BRIT) Corporation Information
8.20.2 Board of Radiation And Isotope Technology (BRIT) - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.20.3 Board of Radiation And Isotope Technology (BRIT) Performance Analysis (2021-2026)
8.20.4 Board of Radiation And Isotope Technology (BRIT) Business and Markets Served
8.20.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments
8.21 Lantheus Medical Imaging, Inc.
8.21.1 Lantheus Medical Imaging, Inc. Corporation Information
8.21.2 Lantheus Medical Imaging, Inc. - Radiopharmaceuticals in Nuclear Medicine Product Portfolio and Specification
8.21.3 Lantheus Medical Imaging, Inc. Performance Analysis (2021-2026)
8.21.4 Lantheus Medical Imaging, Inc. Business and Markets Served
8.21.5 Lantheus Medical Imaging, Inc. Recent Developments

9 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Product Type and End User (2026-2034)
9.1 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Product Type (2026-2034)
9.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth Rate of Diagnostic Nuclear Medicine (2026-2034)
9.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth Rate of Therapeutic Nuclear Medicine (2026-2034)
9.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth Rate of Others (2026-2034)
9.2 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by End User (2026-2034)
9.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth Rate of Hospitals (2026-2034)
9.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth Rate of Specialty Clinics (2026-2034)
9.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth Rate of Diagnostic Centers (2026-2034)
9.2.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth Rate of Others (2026-2034)

10 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Geographic Region (2026-2034)
10.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume and Revenue Forecast by Geographic Region (2026-2034)
10.2 North America Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.2.1 United States Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.2.2 Canada Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3 Europe Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.1 Germany Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.2 France Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.3 United Kingdom Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.4 Spain Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.5 Russia Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.6 Poland Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.1 China Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.2 Japan Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.3 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.4 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.5 India Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.6 Australia Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.5 Latin America Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.5.1 Mexico Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.5.2 Brazil Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.6 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.6.1 GCC Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)
10.6.2 South Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume, Revenue Forecast and Growth (2026-2034)

11 Appendix
11.1 Methodology
11.2 Research Data Source
11.2.1 Secondary Data
11.2.2 Primary Data
11.2.3 Market Size Estimation
11.2.4 Legal Disclaimer